PRNewsWire
12 May 2026, 13:53 UTC · 23w ago
Verdict
Headline takes no side. We score ELVN +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
ELVN-001 achieved a cumulative major molecular response (MMR) rate of 47% and a 24-week MMR rate of 38% in the mature, heavily pretreated 80 mg QD Phase 1b cohort.
More positive than 99% of claims this week
In patients who previously received asciminib, ELVN-001 achieved a cumulative MMR rate of 52%, with 38% of patients achieving MMR by 24 weeks.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 98% of claims this week
ELVN-001 maintained a favorable safety and tolerability profile across 141 enrolled patients with a median treatment duration of approximately 32 weeks.
More positive than 98% of claims this week
Enliven will present updated Phase 1 clinical data with additional patients and longer treatment duration at the EHA 2026 Congress on June 11.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced positive Phase 1 clinical trial data for its CML drug ELVN-001 and an upcoming oral presentation at a major medical congress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
22h ago
+4.9%
Price agrees with the score
$41.52 vs $39.59 close before publication (May 11) · not market-adjusted
ELVN chart →
